>
Inside the Fight ff MI6 and CIA Proxies Over Who Is To Lead Ukraine
The Real Elites vs. The Ruling Elites
The State Spins a New Idea for Recruiting in an Age of War
Woke Nike Booted from S&P 100 as Stock Crashes on Dismal Sales
Floating data center would provide water and electricity to 32,000 homes
OpenAI Cuts Off Elon's Cursor, Humanity's First Star Probe, and Trump's Nuclear Mars Shi
Eating pollution? Plastic-to-cookie technology raises safety, environmental concerns
Ford's $30,000 Fathom EV Truck Appears More Conventional Than Expected
Berlin-based artist Simon Weckert explored that idea with Digital Camouflage...
Tether expands tokenization business into Saudi Arabia, starting with real estate
Ukraine is facing a new problem in its war with Russia:
It charges more than it discharges while driving

In a fair fight, the immune system would wipe out cancer every time – but this crafty disease doesn't play fair. Along with its many tricks to avoid detection, tumors build microenvironments around themselves that are toxic to immune cells, draining them of energy. Sustained immune responses against a pathogen like cancer can lead to T cell exhaustion.
Finding ways to supercharge the immune system to continue the fight is the main goal of immunotherapy. Now, a team from Brigham and Women's Hospital has demonstrated a new way to refresh T cells, by essentially replacing their batteries.
Mitochondria are organelles that produce chemical energy for cells, but during T cell exhaustion these little batteries can be lost or damaged. Previous studies have shown that cancer cells can use nanotubes like "tiny tentacles" to slurp up mitochondria from immune cells. For the new study, the researchers found that they could use the same mechanism to do the opposite – donate new mitochondria to T cells, from bone marrow stromal cells (BMSCs).
The team cultured BMSCs and T cells together, and after 48 hours found that up to a quarter of the T cells had gained extra mitochondria. The researchers dubbed these juiced up immune cells Mito+.
In tests in mice, Mito+ cells were found to more easily penetrate tumors and launch a more robust attack on them. Tumors shrank drastically, and 75% of treated mice survived the full 60-day study period. In contrast, control mice saw their tumors continue to grow, and all had died by the 20-day mark.
Intriguingly, Mito+ cells could multiply quickly and pass their extra mitochondria to the new cells. Other immune cells, such as lymphocytes and CAR-Ts, also showed improved cancer-killing abilities after receiving extra mitochondria.
"These supercharged T cells overcome one of the fundamental barriers of immunotherapy by penetrating the tumor and overcoming immune barren state in the tumor," said Shiladitya Sengupta, corresponding author of the study. "Mitochondria provide the fuel. It's like we're taking T cells to the fuel station and gassing them up. This transplanting of mitochondria is the dawn of organellar therapy – where an organelle is delivered to a cell to make it more effective."